Phase IIa trial of ICT 140 in patients with ovarian cancer at high risk of first recurrence
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 17 Sep 2014
At a glance
- Drugs ICT 140 (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- 17 Sep 2014 Planned number of patients changed from 60 to 56, as reported in an ImmunoCellular Therapeutics media release.
- 13 Jan 2014 Enrolment is expected to begin in the third quarter of 2014, according to an ImmunoCellular Therapeutics media release.
- 08 Aug 2013 Protocol was enhanced to include a larger patient population and a comparator group, according to an ImmunoCellular Therapeutics media release; the study will be at approximately 4 clinical sites.